REVIEW PAPER
A genetic disease under the multiform mask – infantile-onset of Pompe disease
1
Student Scientific Circle at the Department of Paediatrics, Endocrinology, and Diabetology with Cardiology Division, Medical University of Białystok, Białystok, Poland
2
Department of Paediatrics, Endocrinology, and Diabetology with Cardiology Division, Medical University of Białystok, Białystok, Poland
Submission date: 2023-11-24
Final revision date: 2024-02-29
Acceptance date: 2024-03-21
Publication date: 2024-09-19
Corresponding author
Anna Kadłubiska
Klaudia Jadczak, Student Scientific Circle at the Department of Paediatrics, Endocrinology, and Diabetology with Cardiology Division, Medical University of Białystok, Białystok, Poland
Klaudia Jadczak, Student Scientific Circle at the Department of Paediatrics, Endocrinology, and Diabetology with Cardiology Division, Medical University of Białystok, Białystok, Poland
Pediatr Pol 2024;99(3):218-224
KEYWORDS
TOPICS
ABSTRACT
Acid α-glucosidase deficiency – Pompe disease (PD) is a genetic, autosomal recessively inherited disorder leading to impaired glycogen degradation and storage in cells, especially muscles. It occurs with a frequency of 1 : 10,000 – 1 : 40,000 live births. This article presents a currently 14-year-old girl diagnosed with infantile-onset PD. A 15 days old the girl was referred to the hospital due to tachycardia. On examination, reduced muscle tone and hepatomegaly were observed. Electrocardiography showed supraventricular tachycardia. Laboratory tests detected increased hepatic aminotransferase activity. Echocardiography of the heart showed features of hypertrophy of both chambers. The patient was referred to the Children’s Memorial Health Institute in Warsaw. Pompe disease was diagnosed. At 4 months of age, therapy with Myozyme, administered intravenously every other week, was started, and it continues to the present day. Early recognition of PD and initiation of substitution therapy allow its course to be slowed and patients’ lives to be extended.
REFERENCES (27)
1.
Musumeci O, Marca G la, Spada M, et al. LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population. J Neurol Neurosurg Psychiatry 2016; 87: 5-11.
4.
Dasouki M, Jawdat O, Almadhoun O, et al. Pompe disease: literature review and case series. Neurol Clin 2014; 32: 751-776.
5.
Güngör D, Reuser AJJ. How to describe the clinical spectrum in Pompe disease? Am J Med Genet A 2013; 161A: 399-400.
6.
Musumeci O, Marino S, Granata F, et al. Central nervous system involvement in late-onset Pompe disease: clues from neuroimaging and neuropsychological analysis. Eur J Neurol 2019; 26: 442-e35.
7.
Toscano A, Rodolico C, Musumeci O. Multisystem late onset Pompe disease (LOPD): an update on clinical aspects. Ann Transl Med 2019; 7: 284-284.
8.
Reuser AJJ, van der Ploeg AT, Chien YH, et al. GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry. Hum Mutat 2019; 40: 2146-2164.
9.
Bodamer OA, Ronald Scott C, Giugliani R. Newborn Screening for Pompe Disease. Pediatrics 2017; 140.
10.
Chamoles NA, Niizawa G, Blanco M, et al. Glycogen storage disease type II: Enzymatic screening in dried blood spots on filter paper. Clin Chim Acta 2004; 347: 97-102.
11.
Toscano A, Montagnese F, Musumeci O. Early is better? A new algorithm for early diagnosis in late onset Pompe disease (LOPD). Acta Myol myopathies cardiomyopathies Off J Mediterr Soc Myol 2013; 32: 78-81.
12.
Sluiter W, Van Den Bosch JC, Goudriaan DA, et al. Rapid ultraperformance liquid chromatography-tandem mass spectrometry assay for a characteristic glycogen-derived tetrasaccharide in Pompe disease and other glycogen storage diseases. Clin Chem 2012; 58: 1139-1147.
13.
Pascarella A, Terracciano C, Farina O, et al. Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy. J Cell Physiol 2018; 233: 5829-5837.
14.
Van der Ploeg AT, Kruijshaar ME, Toscano A, et al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol 2017; 24: 768-e31.
15.
Winchester B, Bali D, Bodamer OA, et al. Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. Mol Genet Metab 2008; 93: 275-281.
16.
Vissing J, Lukacs Z, Straub V. Diagnosis of Pompe disease: muscle biopsy vs blood-based assays. JAMA Neurol 2013; 70: 923-927.
17.
Tarallo A, Carissimo A, Gatto F, et al. microRNAs as biomarkers in Pompe disease. Genet Med 2019; 21: 591-600.
18.
Ronzitti G, Collaud F, Laforet P, Mingozzi F. Progress and challenges of gene therapy for Pompe disease. Ann Transl Med 2019; 7: 287-287.
19.
Kishnani PS, Goldenberg PC, DeArmey SL, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 2010; 99: 26-33.
20.
De Groot AS, Kazi ZB, Martin RF, et al. HLA- and genotype-based risk assessment model to identify infantile onset Pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA). Clin Immunol 2019; 200: 66-70.
21.
Desai AK, Li C, Rosenberg AS, Kishnani PS. Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review. Ann Transl Med 2019; 7: 285-285.
22.
Khan AA, Case LE, Herbert M, et al. Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature. Genet Med 2020; 22: 898-907.
23.
Kronn DF, Day-Salvatore D, Hwu WL, et al. Management of confirmed newborn-screened patients with Pompe disease across the disease spectrum. Pediatrics 2017; 140.
24.
Kishnani PS, Corzo D, Leslie ND, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 2009; 66: 329-335.
25.
Duro G, Zizzo C, Cammarata G, et al. Mutations in the GLA gene and LysoGb3: is it really Anderson-Fabry disease? Int J Mol Sci 2018; 19.
26.
Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 2017; 377: 1713-1722.
27.
Bortolussi G, Zentillin L, Vaníkova J, et al. Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar Syndrome. Hum Gene Ther 2014; 25: 844-855.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
